914224-34-3

Usage

Uses

Used in Medicinal and Pharmaceutical Research:
2-(4-Nitrophenyl)imidazo[2,1-b]benzothiazol-7-ol is used as a potential drug candidate or a precursor in organic synthesis for its unique structure and potential biological activities. 2-(4-Nitrophenyl)imidazo[2,1-b]benzothiazol-7-ol's synthesis and properties make it valuable for further investigation in the development of new therapeutic agents.
Used in Organic Synthesis:
2-(4-Nitrophenyl)imidazo[2,1-b]benzothiazol-7-ol is used as a precursor in organic synthesis, where the nitro group may provide interesting reactivity and properties. This allows for the exploration of its potential in the creation of new compounds with various applications in different industries.
Used in Chemical Research:
2-(4-Nitrophenyl)imidazo[2,1-b]benzothiazol-7-ol is used in chemical research to study its unique structure, reactivity, and properties. 2-(4-Nitrophenyl)imidazo[2,1-b]benzothiazol-7-ol's synthesis and characteristics make it a valuable subject for further investigation in various scientific fields, potentially leading to new discoveries and applications.

InChI:InChI=1/C15H9N3O3S/c19-11-5-6-13-14(7-11)22-15-16-12(8-17(13)15)9-1-3-10(4-2-9)18(20)21/h1-8,19H

Upstream product

• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 99-81-0 4-Nitrophenacyl bromide 
• 106-51-4 p-benzoquinone 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 

Downstream Products

• 950769-58-1 quizartinib 
• 1132827-21-4 Quizartinib dihydrochloride 
• 1300734-53-5 7-(2-morpholin-D₈-4-yl-ethoxy)-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazole 
• 950769-61-6 2-(4-aminophenyl)-7-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazole 
• 1225542-42-6 7-(2-chloroethoxy)-2-(4-nitrophenyl)imidazo[2,1-b]benzothiazolel 
• 950769-60-5 4-(2-((2-(4-nitrophenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)oxy)ethyl)morpholine 
• 1132827-30-5 4-(7-hydroxyimidazo[2,1-b]benzothiazol-2-yl)benzenamine 
• 950769-74-1 7-(3-chloropropoxy)-2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazole 

Relevant academic research and scientific papers

Benzo imidazo [2, 1-b] thiazole compound and application thereof (by machine translation)

The invention discloses a benzoimidazo [2, 1-b] thiazole compound and application thereof, and belongs to the technical field of medicines. The inhibitory activity of the synthesized benzimidazo [2, 1-b] thiazole analogues on FLTT3 is more than 90%, wherein the compounds (compounds 2 , 4, 6, 8 and 10) are IC of FLTT3-ITD kinase. 50 Lower value, in particular compound 2, IC IC50 The value is only 5.60 nm, and therefore the compound of the present invention may be used as an inhibitor FLTT3, or for preparing a drug capable of modulating or suppressing diseases associated with abnormal cell proliferation by affecting the enzymatic activity of one or more tyrosine kinases and interfering with aberrant cell proliferation, having a wide application prospect. (by machine translation)

Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion

The receptor tyrosine kinase FLT-3 is frequently mutated in acute myeloid leukemia; however, current small molecule inhibitors suffer from limited efficacy in the clinic. Conversion of a FLT-3 inhibitor (quizartinib) into a proteolysis targeting chimera (

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

NEW AMINOACID DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS INHIBITORS OF ONCOGENIC SIGNALS BY THE MET FAMILY

The present invention concerns novel aminoacids derivatives, in particular some aminoacid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.

IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

SOLID FORMS COMPRISING N-(5-TERT-BUTYL-ISOXAZOL-3-YL)-N'-{4-[7-(2-MORPHOLIN-4-YL-ETHOXY)IMIDAZO[2,1-B][1,3]BENZOTHIAZOL-2-YL]PHENYL}UREA, COMPOSITIONS THEREOF, AND USES THEREWITH

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin- 4-yl-ethoxy)imidazo[2,l-b][l,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatmen

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2- morpholin-4-yl-ethoxy)imidazo-[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

Treatment of AML patients with small molecule inhibitors of FLT3 kinase has been explored as a viable therapy. However, these agents are found to be less than optimal for the treatment of AML because of lack of sufficient potency or suboptimal oral pharma

Imidazolothiazole compounds for the treatment of disease

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.